The practice of prescribing medicine has remained fundamentally unchanged for decades: a clinician evaluates a patient, draws on their training and available reference materials, and writes a prescription. What is changing — rapidly and irreversibly — is the quality, accessibility, and intelligence of the tools that support that moment of decision. Digital health technologies and artificial intelligence are not replacing clinical judgement; they are augmenting it in ways that have the potential to significantly reduce prescribing errors, improve adherence to evidence-based guidelines, and ultimately improve patient outcomes [1].
Artificial Intelligence in Prescribing
From Rule-Based Alerts to Machine Learning
The first generation of clinical decision support systems (CDSS) were rule-based: if a patient is prescribed drug A and drug B simultaneously, generate an alert. These systems were effective at flagging known interactions and contraindications, but their high false-positive alert rates led to "alert fatigue" — clinicians dismissing alerts reflexively because the majority were clinically irrelevant [2].
The next generation of CDSS uses machine learning to move beyond static rules. Rather than checking a fixed interaction table, these systems learn from aggregated clinical data to predict adverse events, identify patients at high risk from specific drug exposures, and recommend alternatives tailored to the individual patient's risk profile. A systematic review by Sutton et al. identified 55 distinct clinical decision support systems operating across diverse clinical domains, finding improvements in clinical outcomes, guideline adherence, and medication safety across multiple healthcare settings [2].
Large Language Models and Clinical Knowledge
The emergence of large language models (LLMs) represents a qualitative shift in what AI-assisted clinical tools can do. Where earlier systems could only retrieve and display structured data, LLMs can reason across complex clinical scenarios, synthesise information from multiple sources, and communicate in natural language [1].
In the prescribing context, this means a clinician can query a system in the same way they might ask a senior colleague: "What is the most appropriate antibiotic for a patient with community-acquired pneumonia, penicillin allergy, and an eGFR of 35?" — and receive a contextualised, reasoned response rather than a list of search results. MedNext's AI semantic search, powered by Cloudflare Workers AI and the Llama 3 model, already delivers this capability within the MedNext drug database, enabling natural language clinical queries across 2,866 drugs in the MedNext Audited Proprietary Dataset.
Real-Time Drug Interaction Checking
The traditional model of drug interaction checking — a clinician manually reviewing interactions at the point of prescribing, or relying on retrospective pharmacist review — is structurally inadequate for complex polypharmacy. Real-time, integrated interaction checking embedded into the prescribing workflow is substantially more effective [2].
The next evolution is predictive interaction checking: rather than waiting for two specific drugs to be co-prescribed before generating an alert, predictive systems analyse the patient's entire medication burden and flag emerging risk before harm occurs. This is particularly valuable in the management of patients whose medications evolve rapidly — critically ill patients, cancer patients on complex chemotherapy regimens, post-operative patients on multiple new agents.
MedNext's interaction checker currently covers over 14,600 known drug interactions across the formulary, with severity grading and clinical context for each interaction. The roadmap includes expanding this to predictive risk scoring and integration with patient-level clinical data to move beyond population-level interaction tables toward individually tailored risk assessments.
Personalised Medicine and Pharmacogenomics
The ultimate vision of AI-assisted prescribing is truly personalised medicine — drug selection and dosing guided not just by diagnosis and comorbidities, but by an individual patient's genetic profile, microbiome, and real-time biomarker data [1].
Pharmacogenomics — the study of how genetic variation influences drug response — is the most clinically mature component of this vision. Variants in genes encoding drug-metabolising enzymes (CYP2D6, CYP2C19, CYP2C9), drug transporters, and drug targets predict both drug efficacy and adverse drug reactions across a growing number of drug-gene pairs. Pre-emptive pharmacogenomic testing, where a patient's relevant genetic variants are determined once and used to guide drug selection across their lifetime, is already implemented in several health systems and has been shown to reduce ADR rates for drugs including clopidogrel, warfarin, codeine, and certain antidepressants.
As the cost of genomic testing continues to fall and clinical evidence accumulates, pharmacogenomic guidance will increasingly be incorporated into clinical decision support tools, enabling prescribers to tailor drug choice and dosing to the individual genetic profile with minimal additional cognitive burden.
MedNext's Roadmap for Digital Prescribing
MedNext Formulary is built on a technological foundation designed to evolve with the clinical decision support landscape. The current platform — 2,866 drugs, AI semantic search, 14,600+ drug interactions, 11 dosing calculators, multilingual support across 38 languages — represents the baseline from which more sophisticated features will develop.
The near-term roadmap includes enhanced AI query capabilities for more complex clinical scenarios, expanded drug interaction data with mechanism-based severity grading, integration of pharmacogenomic guidance within drug monographs, and shareable drug information links for multidisciplinary team communication. Longer-term development is focused on personalised risk scoring at the individual patient level, drawing on the convergence of pharmacogenomics, real-world evidence, and AI reasoning capabilities described by Topol as "high-performance medicine" [1].
The future of prescribing is one where the right drug, in the right dose, for the right patient, is not the aspiration — it is the expectation. Digital clinical decision support tools are the infrastructure through which that expectation will be met.
References
- Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44-56.
- Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020;3:17.